TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 09/25/23

Approval is Based on Clinical Studies Conducted in Japan, Europe and North America Confirming the Efficacy and Safety of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] CUVITRU is Takeda’s First Subcutaneous Immunoglobulin Plasma Therapy in Japan, Delivering on the...

2023-09-20 08:52:06 ET More on Takeda Pharmaceutical Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade) ImmunoGen inks deal with Takeda for cancer drug Elahere Takeda pulls marketing application for dengue vaccine in the U.S. Seeking Alph...

Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) resubmission for TAK-721 (budesonide oral suspension) which is being investigated for the short-term treatment of eosinophilic esoph...

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

Takeda’s Five New Partnerships Boost Total Global CSR Program Contributions to JPY 24.2 Billion (Approx. USD 167.5 million) Since Program Inception in 2016. More Than 24,500 Takeda Employees Worldwide Participated in the Selection of the Five New Partnerships: Society for Family He...

2023-09-13 08:30:21 ET More on Takeda Pharmaceutical Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade) Takeda: Upside Case Strengthening, Looking To 15x Earnings ImmunoGen inks deal with Takeda for cancer drug Elahere Takeda pulls market...

− Applications for Investigational Subcutaneous Administrations for Both Crohn’s Disease and Ulcerative Colitis Are Now Under Review by the FDA Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

2023-09-12 17:09:48 ET Summary Wave Life Sciences Ltd. develops stereopure oligonucleotides targeting disease-causing genetic mutations. The company has lead assets in phase 1/2 trials for Duchenne muscular dystrophy and Huntington's Disease. Wave has collaborations with GSK a...

Patient-led Innovations in Inflammatory Bowel Disease Take the Prize in Takeda Canada's Digital Health Challenge Canada NewsWire The 2023 Winners are Ayble Health and IBDrelief TORONTO , Sept. 12, 2023 /CNW/ - Takeda Canada Inc. ("Takeda") is ple...

− Topline Results for TAK-279 Show that a Significantly Greater Proportion of Psoriatic Arthritis Patients Achieved at Least an ACR20 Response Compared to Placebo at Week 12 1 − Based on the Positive Results, Takeda Intends to Initiate a Phase 3 Study of TAK-279 ...